A randomised prospective phase III comparison of paclitaxel - carboplatin versus docetaxel - carboplatin as first line chemotherapy in stage Ic-IV epithelial ovarian cancer

Submission date	Recruitment status No longer recruiting	Prospectively registered		
01/07/2001		☐ Protocol		
Registration date 01/07/2001	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
04/01/2012	Cancer			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00003998

Protocol serial number

G57

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Ovary

Interventions

- 1. Docetaxel 75 mg/m(2) + Carboplatin AUC repeated on day 22 for six cycles
- 2. Paclitaxel 175 mg/m(2) + Carboplatin AUC 5 repeated on day 22 for six cycles

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

carboplatin versus docetaxel

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/05/2000

Eligibility

Key inclusion criteria

- 1. Histologically confirmed epithelial ovarian cancer
- 2. Female
- 3. At least 18 years old
- 4. Stage Ic-IV disease
- 5. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1997

Date of final enrolment

01/05/2000

Locations

Countries of recruitment

United Kingdom

England

Study participating centre UKCCCR Register Co-ordinator

London United Kingdom NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Industry

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Funder Name

Rhone-Poulenc Rorer

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/11/2004		Yes	No